Previous 10 | Next 10 |
Wells Fargo has downgraded life sciences company Thermo Fisher Scientific (NYSE:TMO) to underweight and lowered the price target from $605 to $525, citing an expensive valuation and "material headwinds for the stock ahead". Thermo Fisher (TMO) is trading -4.37% currently and -1...
The shares of Syneos Health (NASDAQ:SYNH) have recorded the worst intraday performance in over two years to reach a 52-week low after Jefferies downgraded the life sciences company to Hold from Buy citing risks to 2022 guidance. Supporting the thesis, the analysts led by David Windley point o...
Demand for COVID-19 vaccines and therapies helped contribute to a 12% increase in spending on medicines in the U.S. in 2021, according to the IQVIA Institute for Human Data Science. U.S. spending on medicines reached $407B last year, with COVID-19 vaccines and therapeutics adding $29B to that...
Despite an increase in overall spending, costs per prescription on average are flat or slightly declining Prescription drug use reached a record level of 194 billion daily doses in 2021 as new prescription starts for both chronic and acute care recovered from the slowdown reco...
With cautious views on the life sciences space, Bank of America slashed the price target of the contract research organization IQVIA Holdings (NYSE:IQV) on Wednesday as the analysts cited estimates to reflect sharper forex headwinds than the company initially projected. The team led by Derik ...
Pharmaceuticals and biotechnology still are attractive regarding value and quality. Other subsectors are overvalued by 15% to 42% relative to 11-year averages. Fast facts on IBB. 10 healthcare stocks cheaper than their peers in April. For further details see: IBB: He...
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its first-quarter 2022 financial results before the market opens on Wednesday, April 27, 2022. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings...
Medpace Holdings is a healthy business trading at a discount to its intrinsic value. Price target $193-200. The company has zero debt vs peer group average of $5.6B debt. Lower risk of permanent loss of capital vs peers. Medpace top-line in the past four years grew at 17.5% CAGR v...
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced that the European Medicines Agency (EMA) has awarded a contract to Erasmus University Medical Center Rotterdam to...
IQVIA™ (NYSE:IQV) today announced the launch of OCE+, the first of several new advancements to its leading life science customer engagement platform. OCE+ adds IQVIA’s Next Best recommendation engine – a daily workflow tool providing AI-driven recommendations for en...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 10:00:13 ET Jailendra Singh from Truist Financial issued a price target of $300.00 for IQV on 2024-07-23 09:26:00. The adjusted price target was set to $300.00. At the time of the announcement, IQV was trading at $240.265. The overall price target consensus is...
2024-07-23 10:00:11 ET Elizabeth Anderson from Evercore ISI issued a price target of $270.00 for IQV on 2024-07-23 08:59:00. The adjusted price target was set to $270.00. At the time of the announcement, IQV was trading at $239.5. The overall price target consensus is at...
2024-07-23 07:00:06 ET Luke Sergott from Barclays issued a price target of $275.00 for IQV on 2024-07-23 05:25:00. The adjusted price target was set to $275.00. At the time of the announcement, IQV was trading at $245.23. The overall price target consensus is at $273.93 ...